1. THU0133 Results from A Phase 2A, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of Jnj-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-Modifying Antirheumatic Drug Therapy. (10th June 2014) Authors: Genovese, M.C.; Hsia, E.; Belkowski, S.; Chien, C.; Masterson, T.; Thurmond, R.; Manthey, C.; Yan, D.; Ge, T.; Greenspan, A. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 224 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗